Compare compounds
Pick up to 3 compounds to see protocols, mechanisms, study endpoints and safety findings side by side.
Peptijournal · Ipamorelin vs Tesamorelin · https://peptijournal.com/compare?c=ipamorelin,tesamorelin · Printed
01Protocol
Ipamorelin
- Start
- 0.1 mg
- Range
- 0.1–0.3 mg
- Frequency
- 1–3× daily
- Cycle
- 8–12 weeks
- Vials
- 5 / 10 mg
Tesamorelin
- Vials
- 10 / 20 mg
- Dosing data
- Lab reference — not listed
02Quick calculator
Ipamorelin
Tesamorelin
03Mechanism of action
Ipamorelin
Ipamorelin is a synthetic pentapeptide that releases growth hormone through the ghrelin (GH secretagogue) receptor, like GHRP-6. It was developed from a GHRP-1 series with the central Ala-Trp dipeptide removed.
Tesamorelin
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH 1-44) with an N-terminal trans-3-hexenoyl modification that improves stability against dipeptidyl peptidase-4 cleavage. It binds GHRH receptors on anterior pituitary somatotrophs, activating Gs/cAMP signaling to stimulate pulsatile endogenous growth hormone release, which in turn raises circulating IGF-1.
04Study endpoints
Ipamorelin
- In rat pituitary cells and in anaesthetised rats and conscious swine, GH-release potency and efficacy were similar to GHRP-6.
- In swine it did not change FSH, LH, prolactin or TSH, and unlike GHRP-6 and GHRP-2 it did not raise ACTH or cortisol across a wide dose range.
- In adult female rats, 15 days of treatment dose-dependently increased longitudinal bone growth (42 to up to 52 µm/day) without changing total IGF-I.
Tesamorelin
- Reduced visceral adipose tissue (VAT) measured by CT in phase 3 trials in HIV-infected adults with abdominal fat accumulation.
- Increased IGF-1 levels while largely preserving physiological pulsatile GH secretion.
- Reduced hepatic fat fraction in HIV-associated fatty liver studies.
- VAT reductions were not maintained after treatment discontinuation in trial extension phases.
05Safety & regulatory findings
Ipamorelin
- Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
- Listed as prohibited in sport by the World Anti-Doping Agency.
- Published evidence is preclinical; no peer-reviewed controlled human efficacy trial is cited here.
Tesamorelin
- FDA-approved in 2010 (Egrifta) specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy.
- Label notes that long-term cardiovascular benefit and safety have not been established, and it is not indicated for weight loss.
- Use outside the approved indication is investigational.